Comirnaty is a vaccine for preventing coronavirus disease 2019 (COVID\-19\) in people from the age of 6 months. As SARS\-CoV\-2 keeps evolving, Comirnaty has been adapted to target the most recent strains of the virus. This helps maintain protection against COVID\-19\. Four versions of Comirnaty are currently authorised: * Comirnaty Omicron XBB.1\.5, which contains raxtozinameran, a messenger RNA (mRNA) molecule with instructions for producing a protein from the Omicron XBB.1\.5 subvariant of SARS\-CoV\-2; * Comirnaty JN.1, which contains bretovameran, an mRNA molecule with instructions for producing a protein from the Omicron JN.1 subvariant of SARS\-CoV\-2; * Comirnaty KP.2, which contains cemivameran, an mRNA molecule with instructions for producing a protein from the Omicron KP.2 subvariant of SARS\-CoV\-2; * Comirnaty LP.8\.1, the most recent version, which contains an mRNA molecule with instructions for producing a protein from the Omicron LP.8\.1 subvariant of SARS\-CoV\-2\. Comirnaty does not contain the virus itself and cannot cause COVID\-19\.
Therapeutic Indication
Comirnaty JN.1 dispersion for injection is indicated for active immunisation to prevent COVID\-19 caused by SARS\-CoV\-2 in individuals 5 years of age and older. The use of this vaccine should be in accordance with official recommendations. Comirnaty JN.1 concentrate for dispersion for injection is indicated for active immunisation to prevent COVID\-19 caused by SARS\-CoV\-2 in infants and children aged 6 months to 11 years. The use of this vaccine should be in accordance with official recommendations. Comirnaty KP.2 dispersion for injection is indicated for active immunisation to prevent COVID\-19 caused by SARS\-CoV\-2 in individuals 5 years of age and older. The use of this vaccine should be in accordance with official recommendations. Comirnaty KP.2 concentrate for dispersion for injection is indicated for active immunisation to prevent COVID\-19 caused by SARS\-CoV\-2 in infants and children aged 6 months to 4 years. The use of this vaccine should be in accordance with official recommendations. Comirnaty LP.8\.1 dispersion for injection is indicated for active immunisation to prevent COVID\-19 caused by SARS\-CoV\-2 in individuals 5 years of age and older. The use of this vaccine should be in accordance with official recommendations. Comirnaty LP.8\.1 concentrate for dispersion for injection is indicated for active immunisation to prevent COVID\-19 caused by SARS\-CoV\-2 in infants and children aged 6 months to 4 years. The use of this vaccine should be in accordance with official recommendations.
Therapeutic Area (MeSH)
ATC Code
J07BN01
ATC Item
N/A
Pharmacotherapeutic Group
Vaccines
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 | N/A | single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 |
EMA Name
Comirnaty
Medicine Name
Comirnaty
Aliases
N/ANo risk management plan link.
